Arcturus
Therapeutics Holdings Inc (NASDAQ:ARCT) said the FDA has granted Orphan Drug
Designation for its lead product candidate ARCT-810 to treat ornithine
transcarbamylase deficiency – the most common urea cycle disorder that makes it
difficult for the removal of toxic waster products as proteins are digested.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a
Financial sector firm, traded 103384 shares in last trading session with
closing price of $9.68 per share. Stock value has moved between $4.1 – 10.3 in
last one year. Analyst’s mean target price for Arcturus Therapeutics Holdings
Inc (NASDAQ:ARCT) is $18.50 while analysts mean recommendation is 1.80. ARCT
EPS growth this year is 38.70%.
On last trading day, Maxim Integrated Products, Inc. (NASDAQ:MXIM) shares
closed at $60.15 per share. MXIM market capitalization is 16366.82 with beta of
1.38. Analyst’s mean target price for Maxim Integrated Products, Inc.
(NASDAQ:MXIM) is $61.78 whereas analysts mean recommendation is 2.80. Its
weekly performance is 3.10% while year to date (YTD) performance is 18.29%.
In last session Bristol-Myers Squibb Company (NYSE:BMY) traded 10.91 Million
shares and was closed at $45.10. Analyst’s mean target price for BMY is $56.10
while analysts mean recommendation is 2.30. Company is -29.19% away from its 52
week high and is moving 1.81% ahead of its 52 week low. BMY Gross Margin is
71.10% and its return on assets is 15.10%. Bristol-Myers Squibb Company
(NYSE:BMY) quarterly performance is -5.73% while its price to sale ratio is
3.16.
Pfizer Inc. (NYSE:PFE), a Healthcare sector firm, traded 20.79 Million shares
on last trading day with closing price of $43.43 per share. Company gross
margin stands at 79.60% whereas its return on investment (ROI) is 10.20%. Stock
value has moved between $35.89 – 46.7 in last one year. Analyst’s mean target
price for Pfizer Inc. (NYSE:PFE) is $45.57 while analysts mean recommendation
is 2.40. PFE EPS growth this year is -11.90%.
FDA granted Orphan Drug Designation for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) lead product
